Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ANRO

Alto Neuroscience Inc.

Sep 06 • 04:00PM ET

13.17

Dollar change +0.45
Percentage change 3.54	%

Healthcare • Biotechnology • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA IWN VTWO SBIO IWC SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	17.79%	Shs Outstand	26.88M	Perf Week	5.36%
Market Cap	355.06M	Forward P/E	-	EPS next Y	-2.72	Insider Trans	0.44%	Shs Float	22.16M	Perf Month	48.48%
Income	-	PEG	-	EPS next Q	-0.62	Inst Own	68.21%	Short Float	14.09%	Perf Quarter	11.89%
Sales	-	P/S	-	EPS this Y	73.16%	Inst Trans	-	Short Ratio	16.08	Perf Half Y	-7.64%
Book/sh	6.67	P/B	1.97	EPS next Y	-4.30%	ROA	-	Short Interest	3.12M	Perf Year	-
Cash/sh	7.16	P/C	1.84	EPS next 5Y	-	ROE	-	52W Range	7.91 - 24.00	Perf YTD	-36.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.12%	Beta	-
Dividend TTM	-	Quick Ratio	19.85	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	66.50%	ATR (14)	0.86
Dividend Ex-Date	-	Current Ratio	19.85	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	62.17	Volatility	6.83% 7.30%
Employees	63	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	33.39
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	-198166.67%	Payout	-	Rel Volume	1.24	Prev Close	12.72
Sales Surprise	-	EPS Surprise	8.63%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	194.16K	Price	13.17
SMA20	21.83%	SMA50	10.98%	SMA200	-1.50%	Trades		Volume	240,418	Change	3.54%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Wedbush	Outperform	$29
Feb-27-24	Initiated	William Blair	Outperform
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	Stifel	Buy	$32
Feb-27-24	Initiated	Robert W. Baird	Outperform	$32
Feb-27-24	Initiated	Jefferies	Buy	$33

Sep-05-24 09:27AM	15 Healthiest Countries in Asia (Insider Monkey) -5.07%
Sep-04-24 08:05AM	Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants (Business Wire)
Sep-03-24 08:05AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-24 04:05PM	Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +9.25% +6.01%
Jul-25-24 08:30AM	Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach (Business Wire)
07:30AM	Loading…
Jul-16-24 07:30AM	Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder (Business Wire) +6.90%
Jul-12-24 01:58PM	Hedge Fund and Insider Trading News: David Tepper, Bill Ackman, Josh Friedman, Whale Rock Capital Management, 352 Capital, Alto Neuroscience Inc (ANRO), Lions Gate Entertainment Corp. (LGF), and More (Insider Monkey)
Jun-20-24 08:05AM	Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia (Business Wire)
Jun-18-24 08:05AM	Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year 2024 Bay Area Award Winner (Business Wire)
Jun-10-24 09:00AM	Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On (InvestorPlace) +5.33%
May-29-24 08:05AM	Alto Neuroscience to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:05AM	Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer (Business Wire)
May-14-24 10:54PM	ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 (InvestorPlace)
04:03PM	Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-09-24 08:05AM	Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences (Business Wire) +5.19%
08:05AM	Loading…
Apr-23-24 08:05AM	Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia (Business Wire)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Apr-09-24 09:37AM	Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Apr-03-24 08:05AM	Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder (Business Wire)
Mar-21-24 04:05PM	Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights (Business Wire) +5.41%
Mar-11-24 08:05AM	Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors (Business Wire) +5.74%
Mar-07-24 08:00AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Feb-27-24 08:00AM	Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference (Business Wire) -6.21%
Feb-06-24 04:05PM	Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) -11.06%
Feb-01-24 08:57PM	Alto Neuroscience Announces Pricing of Upsized Initial Public Offering (Business Wire)

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savitz Adam	CHIEF MEDICAL OFFICER	Jul 09 '24	Buy	12.60	12,069	152,085	36,920	Jul 11 04:15 PM
Savitz Adam	CHIEF MEDICAL OFFICER	Jul 10 '24	Buy	13.22	2,931	38,748	39,851	Jul 11 04:15 PM
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Mar 28 '24	Buy	16.36	6,150	100,628	26,866	Apr 01 04:15 PM
Alpha Wave Global, LP	10% Owner	Feb 06 '24	Buy	16.00	600,000	9,600,000	3,707,757	Feb 08 04:32 PM
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Feb 06 '24	Buy	16.00	1,563	25,008	1,563	Feb 07 04:40 PM
Savitz Adam	CHIEF MEDICAL OFFICER	Feb 06 '24	Buy	16.00	17,000	272,000	24,851	Feb 07 04:38 PM
Etkin Amit	PRESIDENT AND CEO	Feb 06 '24	Buy	16.00	3,125	50,000	1,205,465	Feb 07 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANRO

Alto Neuroscience Inc.

Upgrade your FINVIZ experience